This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Mahidol University, Osaka University. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 9 
1 out of 1,044 
Years Active: 2023
Title: Emi Nakayama: Innovator in Monoclonal Antibodies
Introduction
Emi Nakayama is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her work focuses on combating viral infections, showcasing her dedication to advancing medical science.
Latest Patents
Emi Nakayama holds a patent for "Broad-spectrum monoclonal antibodies against chikungunya virus E1 structural protein." This invention provides a new antibody targeting various types of Chikungunya virus, including ECSA, WA, and Asian types. The antibody comprises a heavy chain variable region and a light chain variable region, which are crucial for its functionality.
Career Highlights
Throughout her career, Emi has worked with esteemed institutions such as Osaka University and Mahidol University. Her research has been pivotal in understanding and developing treatments for viral diseases. She has demonstrated a strong commitment to scientific research and innovation.
Collaborations
Emi Nakayama has collaborated with notable colleagues, including Tatsuo Shioda and Tadahiro Sasaki. These partnerships have enhanced her research efforts and contributed to her success in the field.
Conclusion
Emi Nakayama's work in developing monoclonal antibodies represents a significant advancement in the fight against viral infections. Her innovative spirit and dedication to research continue to inspire future generations of scientists.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile